ABOUT US
Pioneering Global Regenerative Science & Technology
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic fibroblast growth factors (FGF), having six flagship biologics approved for a wide range of indications since 1998.
Our portfolio of products aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas, which include Ophthalmology, Dermatology and Wound Healing.
These products are available in more than 14,100 hospitals, managed directly by our 46 regional sales offices.
Leveraging on our in-house R&D platform in growth factors and antibodies, we maintain a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Our portfolio of products aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas, which include Ophthalmology, Dermatology and Wound Healing.
These products are available in more than 14,100 hospitals, managed directly by our 46 regional sales offices.
Leveraging on our in-house R&D platform in growth factors and antibodies, we maintain a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
1
Research & Development
Research and Innovation Centres located across China, Singapore, United Kingdom and United States.
2
Production
Multiple production lines for drug substances and API, with fill-finish capability catered for preservative free drug products.
3
Sales & Marketing
Entrenched Market Foothold covering more than 14,100 hospitals.
Market leader in growth factor therapeutic products covering Ophthalmology, Dermatology and Wound Healing.
Market leader in growth factor therapeutic products covering Ophthalmology, Dermatology and Wound Healing.
Embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.
Embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
2025.07.24
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023.08.16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023.07.26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023.03.08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021.10.27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021.04.20
粵公網安備 44049102496184號